On March 18, 2025, IceCure Medical Ltd. announced its exhibition at the 19th Annual St. Gallen Breast Cancer Conference in Vienna, Austria, which took place from March 12 to 15, 2025. During the conference, six studies featuring ProSense® in breast cancer were accepted as peer-reviewed abstracts and presented as e-posters. These studies are also slated for publication in the scientific journal, The Breast.
IceCure's CEO, Eyal Shamir, noted the high level of interest in ProSense® at this prestigious European breast cancer conference. The increasing commercial traction in Europe is driven by existing regulatory approval and a growing body of efficacy and safety data from third-party studies. The investigator-initiated studies provide a breadth and depth of data from diverse patient populations and settings.
The company expressed gratitude to the investigators, emphasizing their shared goal of advancing women's health through innovation and collaboration. This continued exposure and validation at major medical events are crucial for driving further adoption of ProSense® as a minimally invasive alternative for breast cancer treatment in Europe and beyond.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.